Mark Levitt

Dr Mark Levitt is a Board Certified Medical Oncologist and Internist in the US and is Specialty Certified as an Oncologist (Medical and Radiation) and Internist in Israel. He received his oncology training at the NCI (USA) and subsequently became Director of the University of Pittsburgh Cancer Institute Pulmonary Oncology Program and an Assistant Professor of Medicine, a KOL in lung cancer and a leader in ECOG. Following his tenure at UPCI, he moved to Allegheny University of the Health Sciences as an Associate Professor of Human Oncology, Head of the Lung Cancer Program, Main Institution PI for ECOG. He also spent a year as Director, Medical Oncology, for the NSABP.

After moving to Israel he became head of the Lung Cancer Unit at Sheba Medical Center and, concurrently, held an Adjunct Professorship at the University of Pittsburgh. He has served as the CSO/CMO of Era Massis, Inc. and Head of Oncology for Inotek Pharmaceuticals. In 2006, he joined Teva as the Global Clinical Oncology Platform Leader in Innovative R&D. In 2009 he became the Global Head of the Oncology Therapeutic Area, Teva Global Business Development and helped lead Teva to the establishment of an Oncology Franchise with the acquisition in 2011 of Cephalon. He continued to serve at Teva until 2013 when he established Levitt Oncology Associates, Ltd.